Noxopharm
(ASX:NOX)

News

Closing Bell: Today’s biggest small cap movers on the ASX

May 7, 2021 | Nick Sundich

News

Last Orders: ASX 200 rebounds, but the IT sector slumps 10 per cent for the week

May 7, 2021May 7, 2021 | Eddy Sunarto

News

Market highlights and 5 ASX small caps to watch on Friday

May 7, 2021 | Eddy Sunarto

Health & Biotech

Cancer trial to test Noxopharm’s Veyonda with Opdivo

March 19, 2021 | Derek Rose

Health & Biotech

Noxopharm study ‘heralds new era’ in treatment of late stage prostate cancer

February 15, 2021February 15, 2021 | Eddy Sunarto

Health & Biotech

Clinical Trials Tracker: 2022 and beyond

January 29, 2021January 26, 2021 | Derek Rose

News

Rise and Shine: What you need to know before the ASX opens

December 3, 2020December 7, 2020 | Sam Jacobs

News

Rise and Shine: What you need to know before the ASX opens

December 2, 2020January 13, 2021 | Nick Sundich

Health & Biotech

The ASX biotech companies that lost puff on Pfizer vaccine news

November 11, 2020November 11, 2020 | Derek Rose

Health & Biotech

Dr Boreham’s Crucible: Kazia reaches the ‘endgame’

September 14, 2020September 14, 2020 | Tim Boreham

Health & Biotech

Aussie biotechs join crusade for COVID-19 cure

September 1, 2020September 1, 2020 | Derek Rose

Health & Biotech

Check up: COVID-19 is back in fashion

July 23, 2020July 23, 2020 | Rachel Williamson

Experts

Scopo’s health powerplays: Clinical trials are back

June 19, 2020October 28, 2020 | Rachel Williamson

Health & Biotech

Check up: Making it in America

May 27, 2020May 27, 2020 | Rachel Williamson

Health & Biotech

COVID-19 treatments are a better bet than a vaccine

May 26, 2020May 27, 2020 | Rachel Williamson

News

Rise and Shine: What you need to know before the ASX opens

May 13, 2020May 13, 2020 | Sam Jacobs

News

Lunchtime ASX Small Cap Wrap: Oily to bed, oily to rise?

April 21, 2020 | Reuben Adams

Health & Biotech

Noxopharm wants to test its anti-prostate cancer drug against COVID-19

April 21, 2020 | Nick Sundich